Web portal for stock market traders

Where can I find historical stock prices for Schering-Plough Corporation (SGP) prior to the mereger with Merck?

ISince Schering-Shove Corp stock is no longer traded, I do not know where to locate historical prices of the stock. If you type in the old symbol SGP in Yahoo it nowe longer comes up.


manifest or college library

you want something called the daily quotation record or similar for the NYSE. it'll probably be a reinforcements item in the Finance section. check their online catalog before going in person.


following or college library

you want something called the daily quotation record or similar for the NYSE. it'll probably be a aloofness item in the Finance section. check their online catalog before going in person.


maybe

Is Nastech a real solid company to Invest in?

Eliminating hype and touting from web spot services and T.V. personality, Cramer, lets really look at this stock objectively.
1)25 years of existence and no major accomplishments
2)No earnings and in reality loses in earnings for all 2007


Too bad Yahoo hasn't creaed a forum called Yahoo Statements or Yahoo Soap Boxes - for undoubtedly that's where this would post :>)


Too bad Yahoo hasn't creaed a forum called Yahoo Statements or Yahoo Soap Boxes - for doubtlessly that's where this would post :>)

Merck KGaA, Millipore Thermo Fischer Scientific STOCK UPDATE.wmv

Jeff Jones is an Associate Portfolio Forewoman of the Gabelli Healthcare & WellnessRX Trust. The above webcast is an excerpt from the WVOX radio ...

Stock Analysis: Merck

The pharmaceutical superhuman reported Q1 earnings that beat the consensus estimate.

Ariad Pharmaceuticals, Inc Elects Merck to Co-Promote ...

Ariad Pharmaceuticals, Inc NASDAQ:ARIA recently announced that it has elected Merck & Flock to co-advance ridaforolimus, an investigational mTOR inhibitor, in the sarcoma omen upon its quiescent approval in the Common States next year. ARIAD and Merck entered into a licensing ahead in May 2010 for the maturation, assembly and commercialization of ridaforolimus in oncology. Based on the terms of the validate contract ARIAD has the election to co-call attention to ridaforolimus with up to 20 percent of the sales striving for the output in all indications in the U.S., and Merck will offset ARIAD for its sales efforts.

...

Read more...

Neutral on Merck - Zacks.com

Analyst Communiqu ) following the rescue of fourth area and 2010 results. Merck reported fourth mercy 2010 earnings per split of 88 cents, 5 cents above the Zacks Consensus Evaluation and 9 cents above the year-ago earnings. Revenues for the domicile climbed 20% to $12.1 billion, above the Zacks Consensus Guestimate of $11.5 billion. Products like Januvia, Janumet, Singulair, Isentress and Remicade performed well during the residence.

...

Read more...

FDA Approves Merck & Co. Inc. (NYSE:MRK) Eye Drug

FDA Approves Merck & Co. Inc. (NYSE:MRK) Eye Painkiller

SAFLUTAN, which is the proposed calling name for tafluprost in the Of like mind States, is Merck & Co. Inc. (NYSE:MRK)’s investigational preservative-loosen prostaglandin analogue ophthalmic explication.

...

Read more...

Dan Kolber: Stock Market News & Commentary: 3/30/11 Wed pm Dow ...

Wednesday's Dow Jones Industrial Normally closing numerator was 1,631.88 up 9.46 from Tuesday's closing numerator of 1,622.42. This is the sum of all 30 closing prices. A penniless cut to...

Read more...

Dan Kolber: Stock Market News & Commentary: 3/30/11 Wed am

A review of Wednesday's Divider Thoroughfare Catalogue, Pecuniary Times, New York Times, USA Today, Atlanta Newsletter Constitution & Regular Communication (Ga. - carries Bloomberg) yielded the following...

Read more...

Stock Prices Merck - News


Today's Must Watch Stocks: Wells Fargo, Eaton, Cooper, Merck, Staples, and Seagate
In the previous 52 weeks, Wells Fargo share prices have been bracketed by a low of US$22.58 and a high of US$34.59, and are now at US$31.40, 39% above that low cost. The company has a market capitalization of 166.86 billion. Since insiders such as CEOs,

Merck CEO: Generics, economy to make 2012-13 tough
Merck CEO: Generics, economy to make 2012-13 tough Price changes in the 10-year note and 30-year thongs are per $100 invested:More >> Just how nervous are investors about Greece? All it took to derail a day of stock market gains was a headline saying that Greece was preparing to off the euro,

Hide from Europe's mess with dividend stocks
By Paul R. La Monica @lamonicabuzzMay 23, 2012: 12:18 PM ET Safer stocks with big dividend yields like Verizon have outperformed the broader merchandise since Europe fears resurfaced about a month ago. NEW YORK () -- Europe's debt woes got you down?



Leave a Reply